Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Tax Provisions: 2014-2025

Historic Tax Provisions for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -$4.2 million.

  • Ascendis Pharma A's Tax Provisions fell 277.48% to -$4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.6 million, marking a year-over-year decrease of 77.05%. This contributed to the annual value of $5.2 million for FY2024, which is 33.29% down from last year.
  • Ascendis Pharma A's Tax Provisions amounted to -$4.2 million in Q3 2025, which was up 2.92% from -$4.4 million recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Tax Provisions peaked at $2.7 million during Q1 2024, and registered a low of -$6.2 million during Q4 2023.
  • Moreover, its 3-year median value for Tax Provisions was -$702,141 (2023), whereas its average is -$1.1 million.
  • The largest annual percentage gain for Ascendis Pharma A's Tax Provisions in the last 5 years was 2,279.71% (2022), contrasted with its biggest fall of 4,083.86% (2022).
  • Over the past 5 years, Ascendis Pharma A's Tax Provisions (Quarterly) stood at -$130,413 in 2021, then tumbled by 4,083.86% to -$5.5 million in 2022, then decreased by 14.19% to -$6.2 million in 2023, then skyrocketed by 81.39% to -$1.2 million in 2024, then slumped by 277.48% to -$4.2 million in 2025.
  • Its Tax Provisions stands at -$4.2 million for Q3 2025, versus -$4.4 million for Q2 2025 and $1.1 million for Q1 2025.